Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study

Abstract

Purpose:To compare the efficacy and tolerability of brinzolamide/timolol (BT) and dorzolamide/timolol (DT) fixed combinations on intraocular pressure (IOP) reduction.Methods:Patients with primary open angle glaucoma or normal tension glaucoma were randomized to receive either BT or DT. IOPs were measured at baseline, 2 weeks, and 1, 2, and 3 months. The primary outcome measures were the mean change in IOP from baseline at each visit. Secondary outcome measures included the tolerability of each fixed combination.Results:Seventy-three patients (73 eyes) were included; 37 eyes in BT group and 36 eyes in DT group. Baseline mean IOP were 24.14 ± 4.5 and 29.53 ± 6 mmHg for BT and DT, respectively (P < 0.001). Both BT and DT provided statistically significant mean IOP reductions from baseline values within each group at all study visits (P < 0.001). DT provided greater mean IOP reductions from baseline than BT at each visit which was statistically significant at 2 weeks (P = 0.037). Mean percentage of IOP reduction was 24.35% and 46.33% at 2 weeks (P < 0.001), and 24.65% and 47% at 3 months (P < 0.001) for BT and DT, respectively. Patients' tolerability appeared to be better for DT than for BT with complete ocular comfort without any ocular adverse effects in 31 patients (81.1%) in DT group and 11 patients (29.7%) in BT group (P < 0.001).Conclusion:Both drops provide effective IOP reduction which was greater, and patients were more likely to achieve lower target pressures with DT than with BT.

Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

“…This FC treatment also has features that may improve long-term adherence to glaucoma therapy, particularly with the added benefits of the recently available PF DTFC formulation. Table 1 lists the several features required of an ideal first-line medication that align with both published evidence [ 17 – 20 , 22 , 29 , 71 , 92 , 112 , 184 ] and clinical experience with DTFC.…”

Pharmaceutical treatment of primary open angle glaucoma

“…The diagnosis type (OAG or OHT) and the number of IOP-lowering medications had no significant influence on the difference in IOP as measured using the two instruments [13]. Dorzolamide/timolol and brinzolamide/timolol FCs effectively decreased IOP, which was a lower target IOP with dorzolamide/timolol than with brinzolamide/timolol, in patients with primary OAG or normal tension glaucoma [44].…”

“…In primary OAG patients, an FC of brinzolamide 1%/brimonidine 0.2% was a safe and effective IOPlowering therapy and provided a significantly greater IOP-lowering activity as compared to either brinzolamide or brimonidine monotherapy [42]. Both FCs of brinzolamide/timolol and of dorzolamide/timolol provided effective IOP reduction, although patients treated with dorzolamide/timolol were more likely to achieve lower target pressures than those treated with brinzolamide/timolol [44]. Both bimatoprost and travoprost effectively decreased IOP, but bimatoprost provided a larger, although statistically non-significant, reduction in mean IOP from baseline [25].…”

Impact of combination of local carbonic anhydrase inhibitors and beta-blockers on intraocular pressure, visual functions and eye hemodynamics in primary open-angle glaucoma

“…Galose и соавт. [59] при изучении эффективности и переносимости терапии ФК дорзоламид/тимолол (рН = 5,6), бринзоламид/тимолол (рН = 7,2) установили, что, несмотря на разницу в рН препаратов группы ИКА и ожидаемую вследствие этого худшую переносимость дорзоламида, частота клинического успеха (достижение целевого ВГД и отсутствие дискомфорта) в группе бринзоламид/тимолол составила 86,5 % (32 из 37 пациентов) по сравнению с 94,4 % (34 из 36 пациентов) в группе дорзоламид/тимолол (p < 0,001). Однако имеются публикации, в которых исследователи отдают предпочтение бринзоламиду в составе фиксированной и нефиксированной комбинаций с тимололом по степени дискомфорта и переносимости лечения [60].…”